Keating Financial Advisory Services’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
Other funds holding CPRX
GCL
HI
Keating Financial Advisory Services's CPRX Position: Q2 2026 in Review
Keating Financial Advisory Services increased its Catalyst Pharmaceutical (CPRX) stake by 15% in Q2 2026, buying an estimated $561 and bringing the position to 144 shares worth $4.53K. The position accounts for ﹤0.01% of the portfolio, ranked #1600.
Keating Financial Advisory Services first reported a position in CPRX in Q4 2025 and has held it in 3 quarters since. The position peaked at $12.2K in Q4 2025. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.
- Keating Financial Advisory Services held 144 shares of Catalyst Pharmaceutical worth $4.53K as of Q2 2026.
- Keating Financial Advisory Services bought 19 Catalyst Pharmaceutical shares in Q2 2026, an estimated $561.
- Catalyst Pharmaceutical made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #1600 holding.
- Keating Financial Advisory Services first reported a position in Catalyst Pharmaceutical in Q4 2025 and has held it in 3 quarters since.
- Keating Financial Advisory Services's Catalyst Pharmaceutical position peaked at $12.2K in Q4 2025.
- 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.
Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.